Meeting
2017 ASCO Annual Meeting
Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors.
Authors
Ben Tran
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Ben Tran , Richard D. Carvajal , Aurelien Marabelle , Sandip P. Patel , Patricia LoRusso , Erik Rasmussen , Gloria Juan , Vijay V. Upreti , Gataree Ngarmchamnanrith , Patrick Schöffski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Antibodies
Clinical Trial Registration Number
NCT02437916
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2521)
DOI
10.1200/JCO.2017.35.15_suppl.2521
Abstract #
2521
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
First Author: Rebecca Sophie Kristeleit
Poster
2015 ASCO Annual Meeting
A phase I study of ARQ 197 in combination with temsirolimus in advanced solid tumors.
First Author: Christos Kyriakopoulos
Poster
2013 ASCO Annual Meeting
A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
First Author: Kari Braun Wisinski
Poster
2023 ASCO Annual Meeting
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.
First Author: Chia-Chi Lin